Grover G J
Department of Pharmacology, Squibb Institute for Medical Research, Princeton, New Jersey 08543-4000.
Proc Soc Exp Biol Med. 1989 Oct;192(1):56-60. doi: 10.3181/00379727-192-42955.
This study was conducted to determine whether the thromboxane A2 receptor antagonist SQ 30,741 can improve post-ischemic recovery of cardiac function in anesthetized dogs. Saline or SQ 30,741 was infused throughout a 15-min coronary occlusion and 5 hr of reperfusion. Ischemic regional cardiac function was determined using subendocardial ultrasonic crystals. Despite no differences in collateral blood flow or reperfusion flow, SQ 30,741 significantly improved ventricular segmental shortening at all times measured during reperfusion. At 5 hr after the initiation of reperfusion, segmental shortening was 3 +/- 16 and 44 +/- 10% of baseline values for saline and SQ 30,741 groups, respectively. These results implicate thromboxane receptor activation in the pathogenesis of myocardial stunning, and thromboxane antagonists may be useful in mitigating this functional deficit.
本研究旨在确定血栓素A2受体拮抗剂SQ 30,741是否能改善麻醉犬缺血后心脏功能的恢复。在15分钟冠状动脉闭塞和5小时再灌注期间持续输注生理盐水或SQ 30,741。使用心内膜下超声晶体测定缺血区域的心脏功能。尽管侧支血流或再灌注血流没有差异,但SQ 30,741在再灌注期间测量的所有时间均显著改善了心室节段缩短。再灌注开始后5小时,生理盐水组和SQ 30,741组的节段缩短分别为基线值的3±16%和44±10%。这些结果表明血栓素受体激活参与了心肌顿抑的发病机制,血栓素拮抗剂可能有助于减轻这种功能缺陷。